Intracellular Therapeutics for Inflammatory Liver Injury

炎症性肝损伤的细胞内治疗

基本信息

  • 批准号:
    7576194
  • 负责人:
  • 金额:
    $ 34.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-01 至 2012-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Alcoholic liver disease (ALD) afflicts an estimated 2 million patients in the US with an astounding 65% mortality rate over a 4 year period. We hypothesize that acute or chronic alcohol abuse alters homeostatic balance that exists between intracellular mediators and suppressors of proinflammatory signaling. This signaling culminates in genetic reprogramming of liver cells manifested by expression of proinflammatory and proapoptotic mediators. We will study how ethanol alters the opposing roles of two key intracellular mediators, signal transducer and activator of transcription (STAT) 1 and 3 in T cell-mediated hepatitis model. The alcohol-induced imbalance between potentially harmful (proapoptotic) signaling mediated by STAT1 and beneficial (anti-apoptotic) signaling mediated by STATS will be studied using our new strategy termed intracellular protein therapy to target proinflammatory and proapoptotic signaling resulting from excessive STAT1 activation. We will expand our successful design and in vivo delivery of physiologic suppressors of cytokine signaling to the cytoplasmic protein known to ablate proinflammatory signaling in macrophages (Kupffer cells) which play a significant role in alcohol-associated inflammatory liver injury. Moreover, we have developed a cell-penetrating nuclear import inhibitory peptide as a prototype of a new class of anti- inflammatory and anti-apoptotic agents which suppresses production of proinflammatory cytokines/chemokines, prevents massive liver apoptosis/necrosis mediated by T cells or macrophages, and reduces mortality rates in animal models. Since this cell-penetrating peptide inhibitor targets intracellular adaptors responsible for nuclear import of stress responsive transcription factors, we will analyze the role of nuclear import adaptors in alcohol-induced injury of liver cells. Cumulatively, we anticipate that the new knowledge gained from these studies will, advance our concept of intracellular protein therapy to extinguish alcohol-exacerbated liver inflammation and apoptosis, and contribute to the development of new therapies for the rapidly failing liver among an estimated 2 million ALD patients in the US. Based on the overall workscope, this grant application is submitted in response to PA-05-074 "Mechanisms of Alcohol-Induced Tissue Injury".
描述(由申请人提供):酒精性肝病(ALD)在美国约有200万患者,4年内死亡率高达65%。我们假设急性或慢性酒精滥用改变了存在于细胞内介质和促炎信号抑制剂之间的稳态平衡。这种信号传导在肝细胞的遗传重编程中达到高潮,表现为促炎和促凋亡介质的表达。我们将研究乙醇如何改变T细胞介导的肝炎模型中两个关键的细胞内介质,信号转导和转录激活因子(STAT)1和3的对立作用。将使用我们称为细胞内蛋白质疗法的新策略来研究酒精诱导的STAT 1介导的潜在有害(促凋亡)信号传导和STATS介导的有益(抗凋亡)信号传导之间的不平衡,以靶向过度STAT 1激活导致的促炎和促凋亡信号传导。我们将扩大我们的成功设计和体内交付的细胞因子信号的生理抑制细胞质蛋白消融巨噬细胞(枯否细胞)中的促炎信号,在酒精相关的炎症性肝损伤中发挥重要作用。此外,我们已经开发了一种细胞穿透性核输入抑制肽作为一类新的抗炎和抗凋亡剂的原型,其抑制促炎细胞因子/趋化因子的产生,防止由T细胞或巨噬细胞介导的大量肝凋亡/坏死,并降低动物模型中的死亡率。由于这种细胞穿透肽抑制剂靶向负责应激反应转录因子核输入的细胞内衔接子,我们将分析核输入衔接子在酒精诱导的肝细胞损伤中的作用。累积起来,我们预计从这些研究中获得的新知识将推进我们的细胞内蛋白质治疗概念,以消除酒精加重的肝脏炎症和细胞凋亡,并有助于开发新的治疗方法,用于治疗美国估计200万ALD患者中迅速衰竭的肝脏。根据总体工作范围,本资助申请是针对PA-05-074“酒精诱导组织损伤的机制”提交的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jack J Hawiger其他文献

Jack J Hawiger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jack J Hawiger', 18)}}的其他基金

Regulation of Innate Immunity and Inflammation Through Nuclear Reprogramming
通过核重编程调节先天免疫和炎症
  • 批准号:
    10002161
  • 财政年份:
    2016
  • 资助金额:
    $ 34.54万
  • 项目类别:
Regulation of Innate Immunity and Inflammation Through Nuclear Reprogramming
通过核重编程调节先天免疫和炎症
  • 批准号:
    9248786
  • 财政年份:
    2016
  • 资助金额:
    $ 34.54万
  • 项目类别:
Regulation of Innate Immunity and Inflammation Through Nuclear Reprogramming
通过核重编程调节先天免疫和炎症
  • 批准号:
    10513826
  • 财政年份:
    2016
  • 资助金额:
    $ 34.54万
  • 项目类别:
Regulation of Innate Immunity and Inflammation Through Nuclear Reprogramming
通过核重编程调节先天免疫和炎症
  • 批准号:
    10339416
  • 财政年份:
    2016
  • 资助金额:
    $ 34.54万
  • 项目类别:
Regulation of Innate Immunity and Inflammation Through Nuclear Reprogramming
通过核重编程调节先天免疫和炎症
  • 批准号:
    9032798
  • 财政年份:
    2016
  • 资助金额:
    $ 34.54万
  • 项目类别:
Intracellular Therapeutics for Inflammatory Liver Injury
炎症性肝损伤的细胞内治疗
  • 批准号:
    7885693
  • 财政年份:
    2009
  • 资助金额:
    $ 34.54万
  • 项目类别:
Targeted Suppression of Cytokine Signaling in the Acute Phase Response
急性期反应中细胞因子信号传导的靶向抑制
  • 批准号:
    7474089
  • 财政年份:
    2008
  • 资助金额:
    $ 34.54万
  • 项目类别:
Targeted Suppression of Cytokine Signaling in the Acute Phase Response
急性期反应中细胞因子信号传导的靶向抑制
  • 批准号:
    7603048
  • 财政年份:
    2008
  • 资助金额:
    $ 34.54万
  • 项目类别:
Targeted Suppression of Cytokine Signaling in the Acute Phase Response
急性期反应中细胞因子信号传导的靶向抑制
  • 批准号:
    7800290
  • 财政年份:
    2008
  • 资助金额:
    $ 34.54万
  • 项目类别:
Intracellular Therapeutics for Inflammatory Liver Injury
炎症性肝损伤的细胞内治疗
  • 批准号:
    7207469
  • 财政年份:
    2007
  • 资助金额:
    $ 34.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了